{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:57:18Z","timestamp":1790477838489,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The pH\u2013induced crystallization of weakly basic drugs in the small intestine limits oral bioavailability. In this study, we investigated the solubilization and inhibitory effects on nintedanib in the presence of enteric polymers (HPMCAS LG, HPMCAS MG, Eudragit L100 55, and Eudragit L100). These polymers provided maintenance of supersaturation by increasing the solubility of nintedanib in PBS 6.8 in a concentration-dependent manner, and the improved ranking was as follows: Eudragit L100 &gt; Eudragit L100 55 &gt; HPMCAS MG &gt; HPMCAS LG. After being formulated into amorphous solid dispersions (ASDs) by a solvent evaporation method, the drug exhibited an amorphous state. The pH shift dissolution results of polymer-ASDs demonstrated that four polymers could effectively maintain the drug supersaturation even at the lowest ratio of nintedanib and polymer (1:1, w\/w). Eudragit L100\u2013ASD could provide both acid resistance and the favorable mitigation of crystallization in GIF. In comparison to the coarse drug, the relative bioavailability of Eudragit L100\u2013ASD was 245% after oral administration in rats, and Tmax was markedly delayed from 2.8 \u00b1 0.4 h to 5.3 \u00b1 2.7 h. Our findings indicate that enteric ASDs are an effective strategy to increase the intestinal absorption of nintedanib by improving physiologically generated supersaturation and subsequent crystallization.<\/jats:p>","DOI":"10.3390\/pharmaceutics14091830","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:13:56Z","timestamp":1661904836000},"page":"1830","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Enteric Polymer\u2013Based Amorphous Solid Dispersions Enhance Oral Absorption of the Weakly Basic Drug Nintedanib via Stabilization of Supersaturation"],"prefix":"10.3390","volume":"14","author":[{"given":"Yuling","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuyao","family":"Xiao","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Li","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-2467","authenticated-orcid":false,"given":"Jiangeng","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqin","family":"Si","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s40262-019-00766-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of nintedanib","volume":"58","author":"Wind","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.canlet.2014.12.027","article-title":"Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer","volume":"358","author":"Awasthi","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fmed.2016.00068","article-title":"Focus on Nintedanib in NSCLC and other tumors","volume":"3","author":"Manzo","year":"2016","journal-title":"Front. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s43018-021-00326-1","article-title":"Selective multi\u2013kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment","volume":"3","author":"Widholz","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"8739","DOI":"10.2147\/IJN.S224044","article-title":"Improving the oral absorption of nintedanib by a self\u2013microemulsion drug delivery system: Preparation and in vitro\/in vivo evaluation","volume":"14","author":"Liu","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13318-018-0467-9","article-title":"Effects of ketoconazole and rifampicin on the pharmacokinetics of nintedanib in healthy subjects","volume":"43","author":"Luedtke","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_7","unstructured":"FDA Center for Drug Evaulation and Research (2014, February 05). Nintedanib Clinical Pharmocology and Biopharmoceutics Review(s), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205832Orig1s000ClinPharmR.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8379","DOI":"10.2147\/IJN.S181002","article-title":"A high bioavailability and sustained\u2013release nano\u2013delivery system for nintedanib based on electrospray technology","volume":"13","author":"Liu","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"106047","DOI":"10.1016\/j.ejps.2021.106047","article-title":"Rod\u2013shaped nintedanib nanocrystals improved oral bioavailability through multiple intestinal absorption pathways","volume":"168","author":"Zhu","year":"2022","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejpb.2008.05.023","article-title":"Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine","volume":"70","author":"Konno","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Qian, K.J., Stella, L., Jones, D.S., Andrews, G.P., Du, H.C., and Tian, Y.W. (2021). Drug\u2013rich phases induced by amorphous solid dispersion: Arbitrary or intentional goal in oral drug delivery?. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060889"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.drudis.2007.09.005","article-title":"Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs","volume":"12","author":"Vasconcelos","year":"2007","journal-title":"Drug Discov. Today"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1021\/acs.molpharmaceut.6b00788","article-title":"Effect of extent of supersaturation on the evolution of kinetic solubility profiles","volume":"14","author":"Han","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajps.2016.10.002","article-title":"Biorelevant test for supersaturable formulation","volume":"12","author":"Lu","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1021\/acs.cgd.7b01521","article-title":"Paclitaxel crystal seeds with different intrinsic properties and their impact on dissolution of paclitaxel\u2013HPMCAS amorphous solid dispersions","volume":"18","author":"Que","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Feng, D., Peng, T., Huang, Z., Singh, V., Shi, Y., Wen, T., Lu, M., Quan, G., Pan, X., and Wu, C. (2018). Polymer\u207bsurfactant system based amorphous solid dispersion: Precipitation inhibition and bioavailability enhancement of itraconazole. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10020053"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1007\/s11095-011-0655-7","article-title":"Stabilization of a supersaturated solution of mefenamic acid from a solid dispersion with EUDRAGIT\u00ae EPO","volume":"29","author":"Kojima","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: The answer to solubility\u2013limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1021\/mp400439q","article-title":"Evolution of supersaturation of amorphous pharmaceuticals: The effect of rate of supersaturation generation","volume":"10","author":"Sun","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejps.2004.10.005","article-title":"Clinical study of solid dispersions of itraconazole prepared by hot\u2013stage extrusion","volume":"24","author":"Six","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/jps.20806","article-title":"Hot\u2013melt extrusion for enhanced delivery of drug particles","volume":"96","author":"Miller","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1080\/03639040801929273","article-title":"Enhanced in vivo absorption of itraconazole via stabilization of supersaturation following acidic\u2013to\u2013neutral pH transition","volume":"34","author":"Miller","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"105043","DOI":"10.1016\/j.ejps.2019.105043","article-title":"Exploration of supersaturable lacidipine ternary amorphous solid dispersion for enhanced dissolution and in vivo absorption","volume":"139","author":"Guan","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijpharm.2016.01.062","article-title":"Solvent\u2013shift strategy to identify suitable polymers to inhibit humidity\u2013induced solid\u2013state crystallization of lacidipine amorphous solid dispersions","volume":"503","author":"Sun","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.carbpol.2017.12.052","article-title":"HPMCAS as an effective precipitation inhibitor in amorphous solid dispersions of the poorly soluble drug candesartan cilexetil","volume":"184","author":"Pinto","year":"2018","journal-title":"Carbohydr. Polym."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1021\/acs.molpharmaceut.8b00633","article-title":"Aggregation of hydroxypropyl methylcellulose acetate succinate under its dissolving pH and the impact on drug supersaturation","volume":"15","author":"Wang","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejpb.2020.07.032","article-title":"An enteric polymer mitigates the effects of gastric pH on oral absorption of poorly soluble weak acid drugs from supersaturable formulations: A case study with dantrolene","volume":"155","author":"Kataoka","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ijpharm.2013.04.052","article-title":"Drug release characteristics from chitosan\u2013alginate matrix tablets based on the theory of self\u2013assembled film","volume":"450","author":"Li","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejpb.2019.06.017","article-title":"The sub\u2013chronic impact of mPEG(2k)\u2013PCL(x) polymeric nanocarriers on cytochrome P450 enzymes after intravenous administration in rats","volume":"142","author":"Li","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhu, W.W., Liu, W.Y., Li, H.J., Xu, G.J., Li, Q., Huang, J.G., Li, G., and Si, L.Q. (2019). Simultaneous Quantitation of a Novel alpha(1)\/beta(1)\u2013Blocker TJ0711 and Its Two Metabolites in Dog Plasma Using LC\u2013MS\/MS and Its Application to a Pharmacokinetic Study after Intravenous Infusion. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11010038"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1021\/cg300325p","article-title":"Understanding polymer properties important for crystal growth inhibition\u2013impact of chemically diverse polymers on solution crystal growth of ritonavir","volume":"12","author":"Ilevbare","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijpharm.2014.01.005","article-title":"The effect of HPMCAS functional groups on drug crystallization from the supersaturated state and dissolution improvement","volume":"464","author":"Ueda","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2008.04.008","article-title":"Comparative evaluation of interpolyelectrolyte complexes of chitosan with Eudragit L100 and Eudragit L100\u201355 as potential carriers for oral controlled drug delivery","volume":"70","author":"Moustafine","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"118562","DOI":"10.1016\/j.carbpol.2021.118562","article-title":"Cellulose derivatives as effective recrystallization inhibitor for ternary ritonavir solid dispersions: In vitro\u2013in vivo evaluation","volume":"273","author":"Guan","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/10837450.2021.1946080","article-title":"The effect of some acrylic polymers on dissolution of celecoxib solid dispersion formulations","volume":"26","author":"Maghsoodi","year":"2021","journal-title":"Pharm. Dev. Technol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijpharm.2019.04.034","article-title":"Amorphous solid dispersions of weak bases with pH\u2013dependent soluble polymers to overcome limited bioavailability due to gastric pH variability\u2014An in-vitro approach","volume":"564","author":"Monschke","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ejpb.2015.06.002","article-title":"Curcumin\u2013Eudragit\u00ae E PO solid dispersion: A simple and potent method to solve the problems of curcumin","volume":"94","author":"Li","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1021\/acs.molpharmaceut.7b01027","article-title":"Enhanced biopharmaceutical performance of rivaroxaban through polymeric amorphous solid dispersion","volume":"15","author":"Metre","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2017.12.016","article-title":"Oral bioavailability enhancement of \u03b2-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion","volume":"124","author":"Liu","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12272-014-0547-6","article-title":"Enhancement of solubility and dissolution of cilostazol by solid dispersion technique","volume":"38","author":"Park","year":"2015","journal-title":"Arch. Pharm. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijpharm.2013.01.067","article-title":"Supersaturatable formulations for the enhanced oral absorption of sirolimus","volume":"445","author":"Kim","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Li, H.L., Zhang, M.M., Xiong, L.L., Feng, W.Y., and Williams, R.O. (2020). Bioavailability improvement of carbamazepine via oral administration of modified\u2013release amorphous solid dispersions in rats. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12111023"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/9\/1830\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:20:28Z","timestamp":1760142028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/9\/1830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["pharmaceutics14091830"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14091830","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}